The dizziness your father's doctor mentioned is not a rare side effect — it is a predictable consequence of how sleep medications interact with an aging body. Older adults metabolize drugs more slowly, which means sedative compounds clear the bloodstream at a fraction of the rate seen in younger patients. The drug that helped someone fall asleep at 10 p.m. may still be pharmacologically active at 3 a.m. when they get up to use the bathroom — exactly when falls are most likely to occur.
A PMC systematic review of zolpidem found a 4.28-fold increased risk of falls in patients taking it, and a relative risk of 1.92 for hip fractures. A 2021 systematic review specifically on zolpidem and balance dysfunction in the elderly confirmed that even at recommended doses, the drug impairs balance in older adults. The FDA-labeled dose for elderly patients is 5 mg for this reason — yet many older adults are prescribed 10 mg.
The dizziness is a signal worth taking seriously. Falls are the leading cause of injury-related death in Americans 65 and older. A broken hip from a nighttime fall often marks a significant and permanent change in an older adult's independence and quality of life.
The medical community has been increasingly clear on this point. The American Geriatrics Society Beers Criteria — the primary reference for potentially inappropriate medications in older adults, updated in 2023 — explicitly recommends against the use of benzodiazepines and benzodiazepine-like drugs (including zolpidem, zaleplon, and eszopiclone) in older adults for insomnia due to their risk of cognitive impairment, delirium, falls, and fractures.
The American College of Physicians and the American Academy of Sleep Medicine both recommend CBT-I as the first-line treatment for chronic insomnia — before medication, not after it has already failed. The fact that your father is on sleep medication and experiencing side effects is precisely the situation these guidelines were written to address.
A landmark October 2025 microsimulation study published in The Lancet Regional Health — Americas modeled what would happen if the 15.3 million Americans over age 50 currently using sleep medication stopped. The findings: eliminating future use would reduce lifetime falls by 8.5%, reduce cognitive impairment by 2.1%, extend life expectancy, and generate $101 billion in net economic savings in the US — largely from improved quality of life and reduced healthcare costs from fall-related injuries.
| Medication | Type | Fall / Dizziness Risk in Elderly | On Beers List? | Notes |
|---|---|---|---|---|
| Zolpidem (Ambien) | Z-drug (GABA agonist) | High — 4.28× increased fall risk; 58% balance loss in elderly subjects | Yes — avoid in older adults | FDA max dose for elderly is 5 mg; many prescribed 10 mg. Dizziness is listed at 3× placebo rate in elderly trials. |
| Eszopiclone (Lunesta) | Z-drug (GABA agonist) | High — similar mechanism to zolpidem; longer half-life increases next-morning impairment | Yes — avoid in older adults | Metallic aftertaste common; 6-hour half-life causes more daytime residual effects in elderly |
| Benzodiazepines (temazepam, lorazepam) | Benzodiazepine (GABA agonist) | Very high — associated with cognitive impairment, delirium, fractures, and motor vehicle accidents | Yes — all benzodiazepines for insomnia in older adults | 2023 Beers Criteria is unambiguous: do not use benzodiazepines for insomnia in older adults |
| Trazodone (off-label) | Sedating antidepressant | Moderate — associated with the highest fall risk among common insomnia medications in a Medicare cohort study | Not on Beers list, but high caution | Often prescribed as "safer" — Medicare claims data found it carries the greatest fall risk among insomnia treatments studied |
| Suvorexant / daridorexant (Belsomra, Quviviq) | Orexin antagonist (DORA) | Lower than Z-drugs — narcolepsy-like symptoms possible; next-day somnolence at higher doses | Not on Beers list | Better safety profile than Z-drugs for older adults; still a symptom suppressant, not a root-cause treatment |
| OTC antihistamines (diphenhydramine / Benadryl, ZzzQuil) | Antihistamine | High — strong anticholinergic effects in elderly cause confusion, memory impairment, and dizziness | Yes — strongly avoid in older adults | Often assumed safe because they're OTC. Particularly dangerous in older adults. Should not be used for insomnia in this age group. |
Yes — and there is now strong evidence specifically in elderly populations. CBT-I was historically developed and studied in younger and middle-aged adults, which led to a misconception that it might be less effective in older patients. Multiple recent studies have put this to rest.
A 2025 randomized controlled trial published in npj Digital Medicine, conducted by researchers at the University of Virginia, enrolled 311 participants aged 55–95 in a digital CBT-I program. Both the self-guided and coach-supported arms showed significant improvements in insomnia severity at post-treatment, 6-month follow-up, and 12-month follow-up compared to the control group. This is among the most comprehensive elderly-specific CBT-I RCTs to date.
A 2025 secondary analysis published in Aging & Mental Health pooled data from three randomized controlled trials of digital CBT-I (Sleepio) in adults aged 65 and older (N = 315). Digital CBT-I significantly improved insomnia, anxiety, and depression symptoms at post-treatment and at 24-week follow-up — outcomes that are especially meaningful given that these conditions often co-occur in older adults.
A 2024 study in the Journal of the American Geriatrics Society evaluated CBT-I in older veterans with chronic insomnia and found it improved insomnia severity, sleep quality, fatigue, and daytime sleepiness — even in those with significant chronic pain, a common comorbidity in older adults.
The consistent finding across this literature: CBT-I is effective in older adults, including those 75 and older, including those with comorbid conditions, and including those who have been on sleep medication for years. Duration of medication use is not a reason to avoid CBT-I — it's precisely the reason to pursue it.
The most important first step is the one that is already happening: his doctor is aware of the problem. The supervised taper must be managed medically — do not reduce or stop any sleep medication without physician guidance. What CBT-I adds is the behavioral foundation that makes the taper sustainable and prevents rebound insomnia from pulling him back to medication.
Here is how the process typically works:
| Phase | What Happens | Who Is Involved |
|---|---|---|
| 1. Medical evaluation | Confirm the current medication, dose, and duration. Assess for any underlying medical causes of insomnia (pain, apnea, nocturia). Establish the taper plan and timeline. | Father's physician — already underway |
| 2. Start CBT-I concurrently | Begin CBT-I while still on current medication. Sleep restriction, stimulus control, and cognitive restructuring begin rebuilding natural sleep architecture before the taper begins reducing the chemical crutch. This approach produces far better outcomes than tapering cold and hoping sleep improves on its own. | Sleep Reset coach + physician |
| 3. Gradual dose reduction | Physician guides a slow taper — typically reducing dose every 2–4 weeks depending on the medication and duration of use. The pace matters: too fast triggers rebound insomnia; too slow prolongs exposure to fall risk. | Father's physician |
| 4. CBT-I fills the gap | As medication dose decreases, the sleep restriction and stimulus control protocols are already working to consolidate sleep naturally. The coach adjusts the sleep window in real time based on nightly sleep diary data. | Sleep Reset coach |
| 5. Off medication | Most patients who complete concurrent CBT-I and a supervised taper successfully discontinue medication. The CBT-I techniques remain — the behavioral and cognitive changes are durable, not dependent on ongoing treatment. | Ongoing physician monitoring; Sleep Reset aftercare |
Research on CBT-I in older adults specifically confirms that it assists hypnotic-dependent patients in tapering off medication and reducing or eliminating future use — with data across multiple studies in elderly populations.
The core concern with any CBT-I program for an older adult is accessibility and support. Sleep restriction is the most effective component of CBT-I and the most demanding — it requires precise calibration, consistent execution, and real-time adjustment when something isn't working. For an older adult navigating this alongside a medication taper, the difference between a self-guided app and a program with a dedicated human coach is significant.
Sleep Reset's sleep coaches review your father's nightly sleep diary, communicate with him daily, and adjust the protocol based on actual progress — including how the taper is interacting with his sleep. This is the level of adaptive, personalized support that the research on CBT-I in older adults consistently identifies as the factor that determines whether patients complete the program.
Sleep Reset also includes licensed sleep medicine clinicians. If his insomnia has a comorbid component — sleep apnea is frequently misidentified as insomnia in older men — home sleep testing and clinical evaluation can identify this before or during the CBT-I program, rather than months later after behavioral treatment has failed to address the underlying cause.
On cost: The CBT-I coaching program is paid out-of-pocket and is HSA/FSA eligible. Where insurance may apply is for Sleep Reset's clinical services — licensed clinician visits and sleep apnea-related care including home sleep testing and apnea treatment are covered by select plans. Check eligibility here.
Yes — and this is the recommended approach. CBT-I is designed to be implemented alongside medication, not only after it is stopped. Starting CBT-I while still on medication gives the behavioral changes time to take hold before the chemical support is reduced. His Sleep Reset coach will be informed of his medication and will adjust the program accordingly. His physician manages the taper; the coach manages the behavioral protocol. Do not reduce medication without his doctor's guidance.
No. The 2025 RCT in npj Digital Medicine enrolled participants up to age 95 and found significant improvements across all age groups. A review in Sleep Medicine Clinics confirms that the same cognitive and behavioral treatments that work in younger adults also work in older adults, including those with comorbid medical conditions. Age is not a contraindication to CBT-I.
CBT-I has been studied in older adults with a wide range of comorbidities, including chronic pain, cancer, cardiovascular disease, and depression, and remains effective. A 2024 study in the Journal of the American Geriatrics Society specifically found that older adults with higher pain levels actually showed greater improvement in insomnia symptoms with CBT-I, not less. Sleep Reset also includes licensed clinicians to manage situations where medical comorbidities require clinical oversight.
When the brain has adapted to a GABA-enhancing sedative like zolpidem, removing it causes a rebound in nervous system excitability — often making sleep temporarily worse than before medication was started. This is a pharmacological withdrawal response, not evidence that your father cannot sleep without a pill. CBT-I addresses the conditioned arousal and depleted sleep drive that rebound insomnia amplifies. Starting CBT-I before or during the taper significantly reduces the severity of rebound insomnia compared to stopping medication alone.
His doctor is best placed to confirm this, and it sounds like they already suspect the connection. Zolpidem specifically has dizziness listed at 3× the placebo rate in elderly clinical trial data. If his current medication is a Z-drug (zolpidem, eszopiclone, zaleplon) or benzodiazepine, the dizziness pattern — typically worst in the first half of the night and upon getting up — is a classic presentation of residual drug effect. Ask his doctor whether the medication he's taking is on the AGS Beers Criteria list, and whether a medication review is appropriate given the fall risk.
The newer orexin antagonists (Quviviq / daridorexant, Dayvigo / lemborexant, Belsomra / suvorexant) have a meaningfully better safety profile than Z-drugs and benzodiazepines for older adults — they are not on the Beers list and do not carry the same fall-related risks. They are a more appropriate pharmacological option if medication is still needed during a CBT-I transition. However, they remain symptom suppressants; they do not treat the underlying insomnia. The goal is to use them as a bridge, not a destination. His physician can advise on whether switching makes sense in his case.
Most people in a structured CBT-I program see meaningful improvement in sleep quality within 2–3 weeks. By weeks 4–6, sleep is typically consolidated enough to support the beginning of a dose reduction. The exact timing should be coordinated between Sleep Reset's coaching team and his prescribing physician, as it depends on his current dose, how long he has been on the medication, and how his sleep responds to the early CBT-I interventions.
Dr. Areti Vassilopoulos | Psychologist | Sleep Medicine Expert
Dr. Vassilopoulos is the Clinical Content Lead for Sleep Reset and Assistant Professor at Yale School of Medicine. She has co-authored peer-reviewed research articles, provides expert consultation to national nonprofit organizations, and chairs clinical committees in pediatric health psychology for the American Psychological Association. She lives in New England with her partner and takes full advantage of the beautiful hiking trails.
Sleep Reset © 2025 All Rights Reserved
.jpeg)
.jpeg)
.jpeg)
.jpeg)
